Cardiac Wire #170 April 22, 2024
AFib’s Downstream Impact | Another IVUS Win
Cardiac Wire #169 April 18, 2024
Echo AI for AFib | MGH’s CT-FFR Impact
Cardiac Wire #168 April 15, 2024
Cardiology’s Industry Payments Problem | Ticagrelor Alone
Cardiac Wire #167 April 11, 2024
Top 8 of ACC 2024 | Getting SMART on SAA TAVR
Cardiac Wire #166 April 8, 2024
Verve’s PCSK9 Pivot | Us2.ai Advances Echo AI
Cardiac Wire #165 April 4, 2024
CXR AI for CVD | TriClip Approved
Cardiac Wire #164 April 1, 2024
Statins’ Diabetes Debate | IPE’s Lp(a) Advantage
Cardiac Wire #163 March 28, 2024
Sotatercept’s PAH Approval | Bempedoic Acid’s Primary Expansion
Cardiac Wire #162 March 25, 2024
Wegovy Gets CVD Coverage | Ticagrelor Advantage
Cardiac Wire #161 March 21, 2024
Fasting Controversy | First BP ERA
Cardiac Wire #160 March 18, 2024
Zerlasiran’s LP(a) Potential | CRT 2024 Highlights
Cardiac Wire #159 March 14, 2024
Wegovy’s CVD Expansion | Painting Away Blockages
Cardiac Wire #158 March 11, 2024
Plastics in Our Plaque | Tendyne’s TMVR Promise
Cardiac Wire #157 March 7, 2024
PROACTIVE’s HF Impact | CAD Breakthrough
Cardiac Wire #156 March 4, 2024
First DCB Approval | Low-Risk ECGs
Cardiac Wire #155 February 29, 2024
Lipoprotein(a)’s CV Risk Thresholds | Intravascular Imaging’s PCI Advantage
Cardiac Wire #154 February 26, 2024
Radiation-Free Interventions | High Protein and CVD
Cardiac Wire #153 February 22, 2024
Transforming ADHF Decongestion | Lp(a)’s Independent Risks
Cardiac Wire #152 February 15, 2024
